Investigators conducted a multiplatform trial to compare the effects of therapeutic-dose heparin with standard care thromboprophylaxis for the treatment of patients hospitalized with moderate COVID-19.
Study authors analyzed data from 10,541 hospitalized patients with active COVID-19 disease to evaluate the relationship between the use of statins and COVID-19 outcomes.
In patients with severe COVID-19 who were deemed not likely to benefit from nIMV, no difference in 30-day mortality was observed for those receiving CPAP or oxygen therapy.
Researchers compared the results of self-collected saliva and anterior nasal swab samples vs nasopharyngeal swab samples collected by healthcare workers used to test for SARS-CoV-2 infection.
In a randomized clinical trial, researchers assessed the effectiveness of umifenovir in combination with other drugs for the treatment of patients hospitalized with moderate to severe COVID-19.
